4-(3-amino-4-methoxybenzyl)-2H-phthalazin-1-one | 623578-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(3-amino-4-methoxybenzyl)-2H-phthalazin-1-one
• 英文别名: 4-[(3-amino-4-methoxyphenyl)methyl]-2H-phthalazin-1-one
• CAS: 623578-55-2
• 化学式: C₁₆H₁₅N₃O₂
• 分子量: 281.314
• InChiKey: HRQILVIGVJZCLS-UHFFFAOYSA-N

物化性质

• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-amino-4-methoxybenzyl)-2H-phthalazin-1-one 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 1-[2-methoxy-5-(4-oxo-3,4-dihydrophthalazin-1-ylmethyl)phenyl]pyrrolidine-2,5-dione
  参考文献：
  名称：

  Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase

  摘要：

  Screening of the Maybridge compound collection identified 4-arylphthalazinones as micromolar inhibitors of PARP-1 catalytic activity. Subsequent optimisation of both inhibitory activity and metabolic stability led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-ones with low nanomolar, cellular activity as PARP-1 inhibitors and promising metabolic stability in vitro. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.026
• 作为产物：
  描述：

  3-硝基-4-甲氧基苯甲醛 在 sodium methylate 、 一水合肼 作用下， 以 甲醇 为溶剂， 生成 4-(3-amino-4-methoxybenzyl)-2H-phthalazin-1-one
  参考文献：
  名称：

  Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase

  摘要：

  Screening of the Maybridge compound collection identified 4-arylphthalazinones as micromolar inhibitors of PARP-1 catalytic activity. Subsequent optimisation of both inhibitory activity and metabolic stability led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-ones with low nanomolar, cellular activity as PARP-1 inhibitors and promising metabolic stability in vitro. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.026

文献信息

• [EN] PHTHALAZINONE DERIVATIVES<br/>[FR] DERIVES DE PHTHALAZINONE
  申请人：KUDOS PHARM LTD

  公开号：WO2003093261A1

  公开（公告）日：2003-11-13

  A compound of formula (I); or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein A and B together represent an optionally substituted, fused aromatic ring; RL is a C5-7 aryl group substituted in the meta position by the group R2, and optionally further substituted; wherein R2 is selected from formula (II) and formula (III); and its use as a pharmaceutical, in particular for the treatment of diseases ameliorated by inhibiting the activity of PARP.

  一种具有化学式（I）的化合物；或其异构体、盐、溶剂合物、化学保护形式、或前药，其中A和B共同代表一个可选择取代的融合芳香环；RL是一个C5-7芳基基团，在邻位由基团R2取代，并可选择进一步取代；其中R2选自化学式（II）和化学式（III）；以及其作为药物的用途，特别用于治疗通过抑制PARP活性改善的疾病。
• Phthalazinone derivatives
  申请人：KuDOS Pharmaceuticals Limited

  公开号：US20040023968A1

  公开（公告）日：2004-02-05

  A compound of formula: 1 or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein A and B together represent an optionally substituted, fused aromatic ring; R L is a C 5-7 aryl group substituted in the meta position by the group R 2 , and optionally further substituted; wherein R 2 is selected from: 2 and its use as a pharmaceutical, in particular for the treatment of diseases ameliorated by inhibiting the activity of PARP.

  一种化合物，其分子式为1或其异构体、盐、溶剂合物、化学保护形式或前药，其中A和B在一起代表一个可选取代的融合芳香环；RL是一个C5-7芳基基团，在meta位被R2基团取代，且可选取进一步取代；其中R2被选自：2，并且它被用作一种药物，特别是用于治疗通过抑制PARP活性改善的疾病。
• PHTHALAZINONE DERIVATIVES
  申请人：Kudos Pharmaceuticals Limited

  公开号：EP1501822B1

  公开（公告）日：2010-12-15
• US7196085B2
  申请人：——

  公开号：US7196085B2

  公开（公告）日：2007-03-27
• Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase
  作者：Vincent M. Loh、Xiao-ling Cockcroft、Krystyna J. Dillon、Lesley Dixon、Jan Drzewiecki、Penny J. Eversley、Sylvie Gomez、Janet Hoare、Frank Kerrigan、Ian T.W. Matthews、Keith A. Menear、Niall M.B. Martin、Roger F. Newton、Jane Paul、Graeme C.M. Smith、Julia Vile、Alan J. Whittle

  DOI：10.1016/j.bmcl.2005.03.026

  日期：2005.5

  Screening of the Maybridge compound collection identified 4-arylphthalazinones as micromolar inhibitors of PARP-1 catalytic activity. Subsequent optimisation of both inhibitory activity and metabolic stability led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-ones with low nanomolar, cellular activity as PARP-1 inhibitors and promising metabolic stability in vitro. © 2005 Elsevier Ltd. All rights reserved.